Based in Israel, Biolojic Design is a startup. Brouky records 1 investor associated with the company.
Biolojic Design computationally designs and programs novel therapeutic antibodies using 3D modeling and machine learning to characterize and engineer antibody binding sites. The company focuses on autoimmune disease and immuno-oncology targets to improve efficacy, specificity, and developability of human antibodies.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.